| __timestamp | Apellis Pharmaceuticals, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 17763000 |
| Thursday, January 1, 2015 | 6356782 | 22180000 |
| Friday, January 1, 2016 | 4303743 | 37257000 |
| Sunday, January 1, 2017 | 10463151 | 27367000 |
| Monday, January 1, 2018 | 22639184 | 64770000 |
| Tuesday, January 1, 2019 | 67046483 | 74986000 |
| Wednesday, January 1, 2020 | 139401000 | 79256000 |
| Friday, January 1, 2021 | 176771000 | 100156000 |
| Saturday, January 1, 2022 | 277163000 | 131408000 |
| Sunday, January 1, 2023 | 500815000 | 152946000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Apellis Pharmaceuticals, Inc. and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Apellis Pharmaceuticals has seen a staggering increase in SG&A expenses, growing from approximately $2.9 million in 2014 to over $500 million in 2023. This represents an exponential growth of over 17,000%. In contrast, Dynavax Technologies' SG&A expenses have increased from about $17.8 million to $152.9 million, marking a more modest growth of around 760%. This stark difference highlights Apellis's aggressive expansion strategy, possibly reflecting its investment in marketing and administrative capabilities to support its growth ambitions. Meanwhile, Dynavax's steadier increase suggests a more conservative approach. These insights provide a window into the strategic priorities of these two biotech firms.
Selling, General, and Administrative Costs: Johnson & Johnson vs Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Dynavax Technologies Corporation
Takeda Pharmaceutical Company Limited or Dynavax Technologies Corporation: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Apellis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing MorphoSys AG and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: ImmunityBio, Inc. vs Dynavax Technologies Corporation
Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Celldex Therapeutics, Inc.